Medical device company NeoVista, Inc., recently announced 12-month results from its MERITAGE study in patients with wet age-related macular degeneration, a leading cause of vision loss in older Americans.
OneMedPlace announced today that its “OneMedForum 2011” business development and finance conference for emerging healthcare and life science companies will be held January 11-13, 2011, in San Francisco at the Sir Francis Drake Hotel.
The administration of the device plus the administration of as-needed anti-VEGF therapy is showing promising results.
The U.S. Food and Drug Administration has approved the first implantable eye telescope to improve vision in patients with end-stage age-related macular degeneration.
The company is focused on the development of medical technologies that to treat wet age-related macular degeneration (AMD).
Discover the latest medtech innovations at this year’s IN3 West conference, which takes place March 3-5 at the Venetian Resort-Hotel-Casino in Las Vegas.
ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
Copyright © 2024 | WordPress Theme by MH Themes